+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

STING Pathway Targeting Therapeutics and Technologies Market, 2020-2030

  • PDF Icon

    Report

  • 328 Pages
  • September 2020
  • Region: Global
  • Roots Analysis
  • ID: 5201300

Overview

In recent years, promising insights from research on the cytosolic DNA sensing (cGAS -STING) pathway has caused a lot of enthusiasm within medical science community. Basically, the STING pathway offers an alternative approach to harnessing the immune system, in order to pharmacologically treat a number of clinical conditions, including oncological and autoimmune disorders. The aforementioned therapeutic benefits can be achieved using modulators of the STING/cGAS-pathway. Over the years, a number of such modulators, capable of either activating or downregulating the STING pathway, have been developed. More than 50 experimental interventions based on this relatively novel concept are currently being developed for the treatment of oncological, autoimmune and inflammatory disorders.

The popularity of STING pathway modulation and growing interest of drug developers in this upcoming field of therapeutics is evident in the rising volume of affiliated scientific literature (1,000+ related articles on NCBI’s PubMed portal since 2015). Moreover, capital investments worth over USD 2.6 billion have been made by various private and public sector investors to fund product development activity. In addition, there have been multiple, high value technology licensing deals in this domain, since 2015. As a result, there has been a considerable rise in number of companies taking initiatives in this field, over the past 4-5 years alone. Interestingly, several big pharma players are also actively evaluating multiple STING agonists/antagonists. It is also worth noting that molecular research into the pathogenesis of the novel SARS-CoV-2 viral strain suggests that COVID-19 may be a STING-related disorder, characterized by delayed over-secretion of IFN-β. STING, in humans, is mostly expressed in lung alveolar epithelial cells, endothelial cells, and spleen cells, which are considered crucial for COVID-19 pathogenesis. Therefore, rapid assessments of STING polymorphisms may actually be useful in identifying individuals who are at high risks of contracting a severe form of this infection. Further, a better understanding of the underlying mechanisms associated with the novel coronavirus induced STING-pathway over-activation, may enable the development of potential therapeutic candidates against COVID-19. Currently, there are no approved STING pathway-targeting drugs/therapy products in the market. However, some promising leads are anticipated to be launched over the coming decade, following which the market is projected to grow at a substantial pace.

Scope of the Report

The “STING Pathway Targeting Therapeutics and Technologies - By Type (Agonist and Antagonist), Molecule (Cyclic Dinucleotides, Non-nucleotides, Live Biotherapeutics, Oncolytic Viruses, Synthetic Peptides and Others), Therapeutic Area (Oncological Disorders, Inflammatory Disorders, Infectious Diseases and Other Diseases), Route of Administration (Intratumoral, Intravenous, Subcutaneous, Oral and Others) and Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2020-2030” report features an extensive study of the current market landscape and future potential of these therapeutics and affiliated technologies, over the next decade. This study focuses specifically on small molecule STING modulators. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.

In addition to other elements, the study includes:


  • A detailed assessment of the current market landscape of therapeutics targeting STING pathway, based on several parameters, such as type of STING modulator (agonist or antagonist), type of molecule (small molecules, cyclic dinucleotides, non-nucleotides, biologics and others), phase of development (discovery, preclinical and clinical), target therapeutic area(s), type of therapy (monotherapy and combination therapy), route of administration (intratumoral, intravenous and others), and line of treatment (last line, second line or greater and first line or greater). The chapter also features an analysis of the developer landscape (including information on year of establishment, company size, geography and most active players). Further the chapter includes an analysis on the clinical trials focused on STING, along with information on parameters, such as recruitment status, study design and clinical endpoints.
  • A detailed chapter highlighting various technology platforms that are being actively used for the development of STING modulators and analysis based on several parameters, such as type of modulator (agonist or antagonist), type of molecule (small molecules, cyclic dinucleotides, non-nucleotides, live biotherapeutics, nanoparticles and synthetic peptides), and analysis based on technology developer landscape (including information on year of establishment, company size and geography).
  • Elaborate profiles of key players that are engaged in the development of therapeutics targeting STING pathway (shortlisted on the basis of phase of development of pipeline products), featuring a brief overview of the company, its financial information (if available), detailed descriptions of their respective lead drug candidates, recent developments and an informed future outlook. Additionally, each drug profile features information on the type of drug, route of administration, target indications and current status of development.
  • Tabulated profiles of industry players (shortlisted on the basis of the antagonist in pipeline products), featuring details on the innovator company (such as year of establishment, location of headquarters, number of employees, key members of the executive team and recent developments), along with descriptions of their respective drug candidates.
  • A study on various grants that have been awarded to research institutes engaged in projects related to STING pathway, during the period 2015 - Q1 2020, based on multiple parameters, such as number of grants awarded, amount awarded, funding institute, support period, funding mechanism, type of grant application, grant activity code, most popular NIH department, type of recipient organization, regional distribution, most popular recipient organization(s), prominent project leader(s) and study section. It also includes an analysis of on grant attractiveness.
  • An analysis of big pharma players engaged in the development of therapeutics targeting STING pathway, based on several parameters, such as portfolio diversity, type of molecule, phase of development, therapeutic area(s), type of therapy and route of administration. In addition, the chapter features a benchmarking analysis of the aforementioned players.
  • An analysis of the start-ups/small players (established in the last ten years, less than 50 employees) engaged in the development of therapeutics targeting STING pathway, based on several relevant parameters, such as portfolio diversity, type of molecule, phase of development, therapeutic area, funding received, number of investors, type of funding, partnership activity, number of patents filed, grants received, and start-up health indexing.
  • A detailed publication analysis of more than 300 peer-reviewed, scientific articles that have been published during the period 2019 - Q1 2020, highlighting the research focus within the industry. It also highlights the key trends observed across publications, including information on type of publication, year of publication, study objective, popular keywords, type of STING modulator, target pathway, therapeutic area, type of publisher, leading players (in terms of number of publications), region, first author organization and key journals (in terms of number of articles published in this domain).
  • An analysis of the partnerships that have been established in the domain, over the period 2015 - Q1 2020, covering research agreements, product/technology licensing agreements, mergers/acquisitions, R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and other relevant deals. The chapter highlights analysis based on year of partnerships, type of partnership model, type of STING modulator, therapeutic area, technology platform, most active player(s) (in terms of number of partnerships inked), and region.
  • An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants/awards, capital raised from IPOs and subsequent offerings, by companies engaged in this field. The chapter highlights analysis based on the number of funding instances, amount invested, type of funding, type of STING modulator, therapeutic area, technology platform, most active player(s) (in terms of number of funding instances), most active investor(s) (in terms of number of funding instances) and geographical region.

One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities for novel technologies designed for the development of STING pathway modulators. Based on the likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided an informed estimate on the evolution of the market over the period 2020-2030. The report features likely distribution of the current and forecasted opportunity across [A] type of STING modulator (agonist and antagonist), [B] type of molecule (non-nucleotides, cyclic dinucleotides, live biotherapeutics, oncolytic viruses, synthetic peptides and others) [C] therapeutic area (oncological disorders, inflammatory disorders, infectious diseases and other disorders), [D] route of administration (intratumoral, intravenous, oral, subcutaneous and others), [E] type of technology licensing payment/revenue (upfront payments and milestone payments) and [F] key geographical regions (North America, Europe and Asia-Pacific). In order to account for future uncertainties associated with the growth of market for therapeutics targeting STING pathway and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain.

The report features detailed transcripts of interviews held with the following individuals:


  • Krzysztof Brzózka (Chris) (Chief Scientific Officer, Ryvu Therapeutics)
  • Glen N Barber (Chief Executive Officer, STINGINN)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.


Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Stimulator of Interferon Genes (STING) Pathway
3.2. STING Signaling
3.2.1. Relevance in Cancer
3.2.2. Relevance in Autoimmune Diseases
3.2.3. Relevance in Antimicrobial Host Defense
3.3. STING Pathway Modulators
3.3.1. STING Agonists
3.3.2. STING Antagonists
3.3.3. STING Activating Drug Delivery Systems
3.3.4. Indirect STING Activating Therapies
3.4. Key Variants of STING
3.5. Non-immunological Functions of the STING Pathway
3.6. Concluding Remarks
4. STING PATHWAY TARGETING THERAPEUTICS: CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. STING Pathway Targeting Therapeutics: Development Pipeline
4.2.1. Analysis by Type of STING Modulator
4.2.2. Analysis by Type of Molecule
4.2.3. Analysis by Phase of Development
4.2.4. Analysis by Therapeutic Area
4.2.5. Analysis by Type of Therapy
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Line of Treatment
4.3. STING Pathway Targeting Therapeutics: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Geography
4.3.4. Most Active Players
4.4. STING Pathway Targeting Therapeutics: List of Clinical Trials
4.4.1. Analysis by Trial Recruitment Status
4.4.2. Analysis by Study Design
4.4.3. Analysis by Key Clinical Endpoints
5. STING PATHWAY TARGETING TECHNOLOGIES: CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. STING Pathway Targeting Technologies: List of Technology Developers
5.2.1. Analysis by Type of Modulator
5.2.2. Analysis by Type of Molecule
5.2.3. Analysis by Year of Establishment
5.2.4. Analysis by Company Size
5.2.5. Analysis by Geography
6. COMPANY PROFILES
6.1. Chapter Overview
6.2 STING Agonist Developers
6.2.1. Aduro Biotech
6.2.1.1. Company Overview
6.2.1.2. Financial Information
6.2.1.3. Product Description: ADU-S100 (MIW815)
6.2.1.4. Recent Developments and Future Outlook
6.2.2. Bristol-Myers Squibb
6.2.2.1. Company Overview
6.2.2.2. Financial Information
6.2.2.3. Product Description: BMS-986301
6.2.2.4. Recent Developments and Future Outlook
6.2.3. Eisai
6.2.3.1. Company Overview
6.2.3.2. Financial Information
6.2.3.3. Product Description: E7766
6.2.3.4. Recent Developments and Future Outlook
6.2.4 GlaxoSmithKline
6.2.4.1. Company Overview
6.2.4.2. Financial Information
6.2.4.3. Product Description: GSK3745417
6.2.4.4. Recent Developments and Future Outlook
6.2.5. ImmuneSensor Therapeutics
6.2.5.1. Company Overview
6.2.5.2. Product Description: IMSA101
6.2.6. Merck
6.2.6.1. Company Overview
6.2.6.2. Financial Information
6.2.6.3. Product Description: MK-1454 and MK-2118
6.2.6.4. Recent Developments and Future Outlook
6.2.7. Noxopharm
6.2.7.1. Company Overview
6.2.7.2. Product Description: NOX66
6.2.7.3. Recent Developments and Future Outlook
6.2.8. Spring Bank Pharmaceuticals
6.2.8.1. Company Overview
6.2.8.2. Financial Information
6.2.8.3. Product Description: SB 11285
6.2.8.4. Recent Developments and Future Outlook
6.2.9. Synlogic
6.2.9.1. Company Overview
6.2.9.2. Financial Information
6.2.9.3. Product Description: SYNB1891
6.2.9.4. Recent Developments and Future Outlook
6.3. STING Antagonist Developers
6.3.1 Avammune Therapeutics
6.3.2. Curadev
6.3.3 ImmuneSensor Therapeutics
6.3.4. Nimbus Therapeutics
6.3.5. Sirenas
6.3.6. Spring Bank Pharmaceuticals
6.3.7. STINGINN
6.3.8. STipe Therapeutics
7. ACADEMIC GRANT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. STING Pathway Targeting Therapeutics: List of Academic Grants
7.3.1. Analysis by Number of Grants
7.3.2. Analysis by Amount Awarded
7.3.3. Analysis by Funding Institute
7.3.4. Analysis by Support Period
7.3.5. Analysis by Funding Mechanism
7.3.6. Analysis by Type of Grant Application
7.3.7. Analysis by Grant Activity Code
7.3.8. Analysis by Funding Institutes
7.3.9. Analysis by Type of Recipient Organization
7.3.10 Regional Distribution of Grant Recipients
7.3.11 Most Popular Recipient Organizations: Analysis by Number of Grants and Amount Invested
7.3.12. Prominent Project Leaders: Analysis by Number of Grants
7.3.13 Analysis by Support Year and Amount Awarded
7.3.14. Analysis by Study Section
7.4. Grant Attractiveness Analysis
8. STING RELATED INITIATIVES OF BIG PHARMACEUTICALS PLAYERS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Initiatives Undertaken by Big Pharma Players
8.3.1. Analysis by Portfolio Diversity
8.3.2. Analysis by Type of Molecule
8.3.3. Analysis by Phase of Development
8.3.4. Analysis by Therapeutic Area
8.3.5. Analysis by Type of Therapy
8.3.6. Analysis by Route of Administration
8.4. Benchmarking Big Pharma Players
8.4.1 Spider Web Analysis: AbbVie
8.4.2. Spider Web Analysis: Bayer
8.4.3. Spider Web Analysis: Bristol-Myers Squibb
8.4.4. Spider Web Analysis: Celgene
8.4.5. Spider Web Analysis: Eisai
8.4.6. Spider Web Analysis: Eli Lily
8.4.7. Spider Web Analysis: Genentech
8.4.8. Spider Web Analysis: GlaxoSmithKline
8.4.9. Spider Web Analysis: Merck
8.4.10. Spider Web Analysis: Novartis
8.4.11. Spider Web Analysis: Novo Nordisk
8.4.12. Spider Web Analysis: Pfizer
8.4.13. Spider Web Analysis: Roche
8.4.14. Spider Web Analysis: Takeda Pharmaceuticals
9. START-UP HEALTH INDEXING
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Benchmarking of Start-ups
9.3.1. Analysis by Portfolio Diversity
9.3.2. Analysis by Type of Molecule
9.3.3. Analysis by Phase of Development
9.3.4 Analysis by Therapeutic Area
9.3.5. Analysis by Funding Amount
9.3.6. Analysis by Number of Investors
9.3.7. Analysis by Type of Funding
9.3.8. Analysis by Partnership Activity
9.3.9. Analysis by Other Parameters
9.3.10. Analysis by Location of Headquarters
9.3.11. Start-up Health Indexing: Perspective
10. PUBLICATION ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. STING Pathway Targeting Therapeutics: Recent Publications
10.3.1. Analysis by Type of Publication
10.3.2. Analysis by Type of Publication and Year
10.3.3. Analysis by Study Objective
10.3.4. Analysis by Popular Keywords
10.3.5. Analysis by Type of STING Modulator
10.3.6. Analysis by Target Pathway
10.3.7. Analysis by Therapeutic Area
10.3.8. Analysis by Type of STING Modulator and Therapeutic Area
10.3.9 Analysis by Type of Publisher
10.3.10. Leading Players: Analysis by Number of Publications
10.3.11. Leading Players: Geographical Analysis by Number of Publications
10.3.12. Analysis by First Author Organization
10.3.13. Key Journals: Analysis by Number of Publications
11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models
11.3. STING Pathway Targeting Therapeutics: Recent Partnerships
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3 Analysis by Type of STING Modulator
11.3.4. Analysis by Therapeutic Area
11.3.5. Analysis by Technology Platform
11.3.6. Most Active Players: Analysis by Number of Partnerships
11.3.7. Geographical Analysis
11.3.7.1 Most Active Players: Analysis by Number of partnerships
11.3.7.2. Intercontinental and Intracontinental Agreements
12. FUNDING AND INVESTMENT ANALYSIS
12.1. Chapter Overview
12.2. Types of Funding
12.3. STING Pathway Targeting Therapeutics: Recent Funding Instances
12.3.1. Analysis by Number of Funding Instances
12.3.2. Analysis by Amount Invested
12.3.3. Analysis by Type of Funding
12.3.4. Analysis by Type of STING Modulator
12.3.6. Analysis by Therapeutic Area
12.3.6 Analysis by Amount Invested and Type of STING Technology Platform
12.3.7. Most Active Players: Analysis by Number of Funding Instances
12.3.8. Most Active Investors: Analysis by Number of Funding Instances
12.3.9. Geographical Analysis by Amount Invested
12.4. Concluding Remarks
13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Forecast Methodology
13.3. Global STING Pathway Targeting Technologies Market, 2020-2030
13.3.1. STING Pathway Targeting Technologies Market by Upfront Payments, 2020-2030
13.3.2. STING Pathway Targeting Technologies Market by Milestone Payments, 2020-2030
13.3.3. STING Pathway Targeting Technologies Market: Distribution by Type of STING Modulator
13.3.3.1. STING Pathway Targeting Technologies Market for Agonist, 2020-2030
13.3.3.2. STING Pathway Targeting Technologies Market for Antagonist, 2020-2030
13.3.4. STING Pathway Targeting Technologies Market: Distribution by Therapeutic Area
13.3.4.1. STING Pathway Targeting Technologies Market for Oncological Disorders, 2020-2030
13.3.4.2. STING Pathway Targeting Technologies Market for Inflammatory Disorders, 2020-2030
13.3.4.3. STING Pathway Targeting Technologies Market for Infectious Diseases, 2020-2030
13.3.4.4. STING Pathway Targeting Technologies Market for Other Therapeutic Areas, 2020-2030
13.3.5. STING Pathway Targeting Technologies Market: Distribution by Route of Administration
13.3.5.1. STING Pathway Targeting Technologies Market for Intratumoral Route, 2020-2030
13.3.5.2. STING Pathway Targeting Technologies Market for Intravenous Route, 2020-2030
13.3.5.3. STING Pathway Targeting Technologies Market for Oral Route, 2020-2030
13.3.5.4. STING Pathway Targeting Technologies Market for Subcutaneous Route, 2020-2030
13.3.5.5. STING Pathway Targeting Technologies Market for Other Routes, 2020-2030
13.3.6. STING Pathway Targeting Technologies Market: Distribution by Type of Molecule
13.3.6.1. STING Pathway Targeting Technologies Market for Non-Nucleotide, 2020-2030
13.3.6.2. STING Pathway Targeting Technologies Market for Cyclic Dinucleotide, 2020-2030
13.3.6.3. STING Pathway Targeting Technologies Market for Live Biotherapeutics, 2020-2030
13.3.6.4. STING Pathway Targeting Technologies Market for Oncolytic Viruses, 2020-2030
13.3.6.5. STING Pathway Targeting Technologies Market for Synthetic Peptides, 2020-2030
13.3.6.6. STING Pathway Targeting Technologies Market for Other Molecules, 2020-2030
13.3.7. STING Pathway Targeting Technologies Market: Distribution by Geography
13.3.7.1. STING Pathway Targeting Technologies Market in North America, 2020-2030
13.3.7.2. STING Pathway Targeting Technologies Market in Europe, 2020-2030
13.3.7.3. STING Pathway Targeting Technologies Market in Asia-Pacific, 2020-2030
14. EXECUTIVE INSIGHTS
15. CONCLUDING REMARKS
15.1. Chapter Overview
15.2. Key Takeaways
16. APPENDIX 1: TABULATED DATA

Companies Mentioned

  • 6 Dimensions Capital
  • Aalborg University
  • Aarhus University
  • AbbVie
  • Abingworth
  • Academia Sinica
  • Actym Therapeutics
  • Aduro Biotech
  • Aescap 2.0
  • AJU IB Investment
  • Alaska Permanent Fund
  • Alexandria Venture Investments
  • All India Institute of Medical Sciences
  • Allergan
  • Ally Bridge Group
  • Almac Diagnostics
  • Alpine BioVentures
  • Atlas Venture
  • Amgen
  • Anhui University of Science and Technology
  • Arbutus Biopharma
  • ARCH Venture Partners
  • Arctic Aurora LifeScience
  • Arix Bioscience
  • Arizona State University
  • Army Medical University
  • Arrowpoint Partners
  • Artimmune
  • Astellas Pharma
  • AstraZeneca
  • Avammune Therapeutics
  • Baruch S. Blumberg Institute
  • Bayer
  • Baylor University Medical Center
  • Beatson Institute
  • BellBrook Labs
  • Beth Israel Deaconess Medical Center
  • Bicycle Therapeutics
  • Bill & Melinda Gates Foundation
  • Biogen
  • BioInnovation Institute
  • Institut de Recerca Biomèdica de Lleida (IRBLleida)
  • BioNovion
  • Boehringer Ingelheim
  • Boston Children's Hospital
  • Boston University
  • Boxer Capital
  • Bpifrance
  • Brigham And Women's Hospital
  • Bristol-Myers Squibb
  • BWG Invest
  • California Institute for Biomedical Research
  • Cambridge Innovation Capital
  • The Beatson Institute
  • Cancer Therapeutics CRC
  • Canterbury Urology Research Trust
  • Casdin Capital
  • Case Western Reserve University
  • Celgene
  • Central South University
  • Center for AIDS Research
  • CHA University
  • Chaim Sheba Medical Center
  • Charité Universitätsmedizin Berlin
  • Charles River Laboratories
  • Charles University
  • Chengwei Capital
  • China Pharmaceutical University
  • Chinese Academy of Agricultural Sciences
  • Chinese Academy of Medical Sciences
  • Chongqing Medical University
  • Chulalongkorn University
  • Cincinnati Childern's Hospital Medical Center
  • CLI Ventures
  • Clough Capital Partners
  • Codiak BioSciences
  • College of Biotechnology Southwest University
  • Columbia University Medical Center
  • CordenPharma
  • Cristal Therapeutics
  • CSL
  • CST Investment Funds
  • Curadev Pharma
  • Curative Ventures
  • Czech Academy of Sciences
  • Daiichi Sankyo
  • Dalhousie University
  • Dana-Farber Cancer Institute
  • David Geffen School of Medicine
  • Deaconess Medical Center
  • Deerfield Management
  • Dermatology Hospital of Fuzhou
  • Dezful University of Medical Sciences
  • DiscoveryBioMed
  • Duke University Medical Center
  • Ecole polytechnique fédérale de Lausanne
  • EcoR1 Capital
  • Ege University
  • Eight Roads Ventures
  • Eisai
  • Eli Lilly
  • Emory University School of Medicine
  • Eulji University School of Medicine
  • European Institute of Oncology
  • Evonik Nutrition & Care
  • Feinstein Institutes for Medical Research
  • Ferring Pharmaceuticals
  • Fidelity Biosciences
  • Flagship Pioneering
  • Florida State University
  • Fluorinov Pharma
  • Fondazione IRCCS Istituto Nazionale dei Tumori
  • Foresite Capital
  • Fox Chase Cancer Center
  • F-Prime Capital
  • Franklin Advisers
  • Frazier Healthcare Partners
  • Fredrick National Laboratory for Cancer Research
  • Fudan University
  • Fujian Medical University
  • Fund+
  • Gachon University
  • Geisel School of Medicine
  • Genentech
  • GenesisCare
  • George Clinical
  • Georges-Francois Leclerc Cancer Center- UNICNACER
  • Ghent University Hospital
  • Gifu University Graduate School of Medicine
  • Gilead Sciences
  • Ginkgo Bioworks
  • GlaxoSmithKline
  • Green Park & Golf Ventures
  • Griffith University
  • Guangzhou Medical University
  • Guilin Medical University
  • Gunma University
  • H3Biomedicine
  • Hacettepe University
  • Hackensack University John Theurer Cancer Center
  • Hallym University
  • Harbin Veterinary Research Institute
  • Harvard Medical School
  • HBM Partners
  • Health Wildcatters
  • Helmholtz Centre for Infection Research
  • Henan Agricultural University
  • HitGen
  • Hong Kong University of Science & Technology
  • Huntsman Cancer Institute
  • Icahn School of Medicine at Mount Sinai
  • IFM Therapeutics
  • ImaBiotech
  • ImmuneSensor Therapeutics
  • IMMvention Therapeutix
  • Inflammatory Bowel Disease Center
  • Inserm
  • Institute of Materia Medica
  • Institute of Radiation Biology
  • Institut Curie
  • Gustave Roussy
  • Institute for Personalized Medicine
  • Institute of Macromolecular Chemistry ASCR
  • Institute of Pathogen Biology
  • InvivoGen
  • Invus
  • Iowa State University
  • iOx Therapeutics
  • IQVIA
  • Istanbul Technical University
  • Istituto Superiore di Sanità
  • iTeos Therapeutics
  • James Graham Brown Cancer Center
  • Janus Capital Management
  • Japanese Foundation for Cancer Research
  • Jazz Pharmaceuticals
  • Jennison Associates
  • Jilin University
  • Johns Hopkins University School of Medicine
  • Juntendo University School of Medicine
  • Kalinga Institute of Industrial Technology
  • Kangwon National University
  • Karmanos Cancer Institute
  • Karol Marcinkowski University of Medical Sciences
  • Karolinska Institute
  • Kazia Therapeutics
  • Keystone Symposia
  • Kindeva Drug Delivery
  • Kobe University
  • Korea Advanced Institute of Science and Technology
  • KU Leuven
  • Kuang Tien General Hospital Cancer Center
  • Kunming University of Science and Technology
  • RIKEN Center for Integrative Medical Sciences Laboratory for Cell Signaling
  • Lerner Research Institute
  • Les Laboratoires Servier
  • LIDDS
  • Life Science Venture Capital Management
  • Lightstone Ventures
  • Linköping University
  • Longwood Fund
  • Lund University
  • Magee- Womens Research Institute
  • Maria Skłodowska-Curie National Research Institute of Oncology
  • Mary Crowley Cancer Research
  • Massachusetts General Hospital
  • Massachusetts Green High Performance Computing Center
  • Massachusetts Institute of Technology
  • Max Planck Institute for Immunobiology and Epigenetics
  • Mayo Clinic
  • Medical College of Wisconsin
  • Medigen
  • Medison Finance
  • Meharry Medical College
  • Memorial Sloan Kettering Cancer Center
  • Merck
  • Mersana Therapeutics
  • Michigan State University
  • Mirna Therapeutics
  • Moffitt Cancer Center
  • Monash University
  • Morningside Group
  • Mount Sinai Hospital
  • MPM Capital
  • MUSC Hollings Cancer Center
  • Nanchang University
  • Nanjing Agricultural University
  • Nanjing Medical University
  • Nankai Univeristy
  • Nanobiotix
  • National Center of Biomedical Analysis
  • National Institutes of Biomedical Innovation, Health and Nutrition
  • National Institutes of Health
  • National Tsing Hua University
  • National Yang-Ming University
  • New Enterprise Associates
  • New York Medical College
  • Newcastle University
  • NEXT Oncology
  • Nimbus Therapeutics
  • Ningxia university
  • Northwest A&F University
  • Northwestern University
  • Novartis
  • Novo Nordisk
  • Noxopharm
  • Nyenburgh Holding
  • Ohio State University College of Medicine
  • Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
  • Oklahoma State University
  • Omega Funds
  • OncoArendi Therapeutics
  • Oncology Impact Fund
  • OnCore Biopharma
  • OrbiMed HealthCare Fund Management
  • Oregon Health & Science University
  • Cormorant Asset Management
  • Osaka City University
  • Otsuka Holdings
  • Otto von Guericke University Magdeburg
  • Pasteur Institute
  • Peking University
  • Penn State College of Medicine
  • Perceptive Advisors
  • Pfizer
  • Portage Biotech
  • Precision for Medicine
  • Princeton University
  • Providence Cancer Institute
  • Purdue University
  • Qatar Investment Authority
  • Quan Capital
  • Queen's University
  • RA Capital Management
  • Radboudumc
  • Rambam Health Care Center
  • Recepta Biopharma
  • Research Institute of Clinical Medicine
  • Roche
  • Rock Springs Capital Management
  • Rockefeller University
  • Roivant Sciences
  • Royal Marsden NHS Foundation Trust
  • Royal North Shore Hospital
  • RTW Investments
  • Rush University Medical Center
  • Ryvu Therapeutics
  • Salk Institute for Biological Studies
  • Sanford Burnham Prebys Medical Discovery Institute
  • Sanford Cancer Center
  • Sanofi
  • Sapienza University
  • Schrödinger
  • Scientipôle
  • Seoul National Univesity
  • Sequoia Capital
  • Severance Hospital
  • SFPI
  • Shandong University
  • Shanghai Jiao Tong University
  • Shire
  • Sichuan Agricultural University
  • Sichuan University
  • Silicon Therapeutics
  • Sirenas
  • Sirona Capital
  • Smorodintsev Research Institute of Influenza
  • SMS-oncology
  • Société Régionale d'Investissement de Wallonie
  • SOTIO
  • South China Agricultural University
  • Southern Medical University
  • Spring Bank Pharmaceuticals
  • Springhood Ventures
  • SR One
  • St. Jude Children's Research Hospital
  • Saint Louis University School of Medicine
  • St. Vincent’s Hospital
  • Stanford University
  • Stimunity
  • STINGINN
  • Stingray Therapeutics
  • STipe Therapeutics
  • Stockholm University
  • Sun Yat-sen University Cancer Center
  • Sunstone Life Science Ventures
  • SV Life Sciences
  • Swiss Federal Institute of Technology
  • Sylvester Comprehensive Cancer Center
  • Synlogic
  • Takeda Pharmaceutical
  • Tbilisi State Medical University
  • Technical University of Munich
  • Technische Universität Dresden
  • Tempest Therapeutics
  • Texas A&M Health Science Center
  • The Lind Partners
  • Thomas Jefferson University
  • Tohoku University
  • Tongji University
  • Trillium Therapeutics
  • Trinity Biomedical Sciences Institute
  • Tsinghua University
  • ttopstart
  • Tufts University
  • Tulane University
  • TWINCORE-Centre for Experimental and Clinical Infection Research
  • Umeå University
  • UND Life Sciences
  • Universidad Autónoma de Madrid
  • Universidad Nacional de Río Cuarto
  • Universidade do Porto
  • Universidade Federal de Minas Gerais
  • Université de Lyon
  • Université libre de Bruxelles
  • University of Alabama Comprehensive Cancer Center
  • University of Arizona Cancer Center
  • University of Bonn
  • University of Buenos Aries
  • University of Calgary
  • University of California
  • University of Cambridge
  • University of Chicago
  • University of Cincinnati
  • University of Clermont Auvergne
  • University of Colorado School of Medicine
  • University of Connecticut School of Medicine
  • University of Delhi
  • University of Edinburgh
  • University of Ferrara
  • University of Florida
  • University of Freiburg
  • University of Glasgow
  • University of Groningen
  • University of Hong Kong
  • University of Illinois College of Medicine
  • University of Kansas
  • University of Konstanz
  • University of Maryland
  • University of Massachusetts Medical School
  • University of Miami
  • University of Michigan
  • University of New South Wales
  • University of North Carolina
  • University of Orleans
  • University of Oxford
  • University of Pennsylvania
  • University of Piemonte Orientale
  • University of Pittsburgh
  • University of Queensland
  • University of Rhode Island
  • University of South China
  • University of South Florida
  • University of Southern California
  • University of Texas MD Anderson Cancer Center
  • University of Texas Southwestern Medical Center
  • University of Tokyo
  • University of Toronto
  • University of Utah
  • University of Veterinary Medicine Hannover
  • University of Virginia
  • University of Washington
  • University of Zurich
  • University of Massachusetts Medical School
  • UPMC Hillman Cancer Center
  • Uppsala University
  • UT Southwestern Medical Center
  • Vanderbilt University
  • VENENUM Biodesign
  • Ventus Therapeutics
  • Versant Ventures
  • Vertex Ventures
  • VIVES Fund
  • Vyriad
  • Wake Forest School of Medicine
  • Washington University School of Medicine
  • Wayne State University
  • Weill Cornell Medicine
  • Weizmann Institute of Science
  • Wellington Management Company
  • Wikow Invest
  • Wuhan University
  • WuXi AppTec
  • Xi'an Jiaotong University
  • Xi'an Medical University
  • Xuzhou Medical University
  • Yale Cancer Center
  • Yangzhou University
  • Yokohama City University
  • York University
  • Zhejiang University School of Medicine
  • Zhengzhou University

Methodology

 

 

Loading
LOADING...